Patent Filing

A new FDA-cleared test detects RSV, Flu A/B, and COVID from a single swab, offering a powerful diagnostic tool for families, especially for infants.

Swedish biotech innovator Hansa Biopharma wins a top award for its life-saving transplant tech, facing a pivotal year with FDA review on the horizon.

As founder Patrick Gruber steps back, incoming CEO Paul Bloom is set to commercialize Gevo's green tech, focusing on profitability and its ambitious SAF goals.

Canadian giant Aurora Cannabis gains exclusive EU rights for two key strains, signaling a new era of genetic ownership in Europe's booming medical market.

A novel cell therapy for Parkinson's earns a key FDA designation, signaling a potential paradigm shift from managing symptoms to reversing the disease.

Kent Imaging denies patent infringement claims from rival MolecuLight over its new SnapshotGLO device, sparking a high-stakes legal battle at the ITC.

A Pennsylvania court denied class action status in a lawsuit over EtO emissions, a second major legal win for B. Braun that reshapes the litigation landscape.

After a career-ending injury, a singer stages a massive comeback with hit songs, new patents, and a story of incredible resilience and reinvention.

With a key drug in late-stage trials and a bolstered team, Palvella Therapeutics aims to deliver the first FDA-approved therapies for rare skin diseases.

Azafaros presents its promising drug, nizubaglustat, for untreatable rare neurological disorders, backed by major funding and late-stage clinical trials.

Vera Therapeutics' novel IgAN drug gets FDA fast-track review, promising a new at-home treatment for a debilitating autoimmune kidney disease.

With its massive data library and AI platforms, Tempus AI prepares for a pivotal presentation. What will CEO Eric Lefkofsky reveal to investors?

With a key drug decision looming and a refocused strategy, Rocket Pharmaceuticals faces a critical audience at the J.P. Morgan Healthcare Conference.

After resolving a key manufacturing issue, Unicycive has resubmitted its kidney drug NDA, offering new hope for dialysis patients with a lower pill burden.

A Los Angeles jury found Johnson & Johnson liable for causing ovarian cancer, a landmark verdict that renews the company's legal battles over its talc products.

From biopharma to webcomics, shareholder lawsuits reveal the perils of misleading investors. A look at four companies facing legal and financial fallout.

With FDA alignment for its pivotal Phase 3 trial, Oncolytics Biotech is poised to bring the first immunotherapy to the challenging pancreatic cancer landscape.

A startup's legal victory protects its revolutionary wound care tech derived from the axolotl, paving the way for a new era in regenerative medicine.

Roivant Sciences reveals accelerated timelines for key drugs and a bold three-year growth plan, pivoting its unique 'Vant' model toward commercialization.

Daré Bioscience is targeting a 20M-woman market with a novel arousal cream. This is the story of its clever regulatory strategy and high-stakes bet.